Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

被引:78
作者
Ling, Z
Wu, D
Zambre, Y
Flamez, D
Drucker, DJ
Pipeleers, DG
Schuit, FC
机构
[1] Free Univ Brussels, Fac Med, Ctr Diabet Res, B-1090 Brussels, Belgium
[2] Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON, Canada
来源
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY | 2001年 / 438卷 / 04期
关键词
GLP-1; receptor; islet; morphometry;
D O I
10.1007/s004280000374
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Glucagon-like peptide 1 (GLP-1) amplifies glucose-induced insulin release in vivo and in vitro. Activation of GLP-1 receptor (GLP-1R) signaling leads to differentiation of exocrine cells towards a beta -cell phenotype in vitro and stimulation of islet cell proliferation in vitro and in vivo, suggesting a potential role for GLP-1 in the modulation of islet growth and differentiation. To determine whether basal levels of GLP-1R signaling are essential for islet development, we examined islet cell composition and topography in GLP-1R-/- mice. Total beta -cell volume and number are not altered, but the topography of beta cells is markedly different in GLP-1R-/- mice compared with GLP-1R+/+ controls. The distribution of beta cells is shifted from large to small and medium-sized islets in the absence of GLP-1R signaling (large islets: 50 +/-3% in GLP-1R+/+ vs 28 +/-4% in GLP-1R-/-, P <0.01 and medium islets: 32 +/-2% in GLP-1R+/+ vs 48 +/-3% in GLP-1R-/-, P <0.001). Further morel GLP-1R-/- islets exhibit abnormalities in cell topography, with two to threefold more centrally located a cells detected in GLP-1R-/- islets. These alterations in alpha- and beta -cell topography indicate that basal levels of GLP-1 signaling in the normal rodent are involved in the normal cellular organization of the endocrine pancreas.
引用
收藏
页码:382 / 387
页数:6
相关论文
共 18 条
[1]
NEW PERSPECTIVES ON THE MICROVASCULATURE OF THE ISLETS OF LANGERHANS IN THE RAT [J].
BONNERWEIR, S ;
ORCI, L .
DIABETES, 1982, 31 (10) :883-889
[2]
Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles [J].
Bruning, JC ;
Winnay, J ;
BonnerWeir, S ;
Taylor, SI ;
Accili, D ;
Kahn, CR .
CELL, 1997, 88 (04) :561-572
[3]
Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells [J].
Buteau, J ;
Roduit, R ;
Susini, S ;
Prentki, M .
DIABETOLOGIA, 1999, 42 (07) :856-864
[4]
GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL [J].
DALESSIO, DA ;
KAHN, SE ;
LEUSNER, CR ;
ENSINCK, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2263-2266
[5]
Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?) [J].
Edvell, A ;
Lindström, P .
ENDOCRINOLOGY, 1999, 140 (02) :778-783
[6]
Neural cell adhesion molecule (N-CAM) is required for cell type segregation and normal ultrastructure in pancreatic islets [J].
Esni, F ;
Täljedal, IB ;
Perl, AK ;
Cremer, H ;
Christofori, G ;
Semb, H .
JOURNAL OF CELL BIOLOGY, 1999, 144 (02) :325-337
[7]
Mouse pancreatic β-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene [J].
Flamez, D ;
Van Breusegem, A ;
Scrocchi, LA ;
Quartier, E ;
Pipeleers, D ;
Drucker, DJ ;
Schuit, F .
DIABETES, 1998, 47 (04) :646-652
[8]
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype [J].
Flamez, D ;
Gilon, P ;
Moens, K ;
Van Breusegem, A ;
Delmeire, D ;
Scrocchi, LA ;
Henquin, JC ;
Drucker, DJ ;
Schuit, F .
DIABETES, 1999, 48 (10) :1979-1986
[9]
KREYMANN B, 1987, LANCET, V2, P1300
[10]
Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor (-/-) mice [J].
Pederson, RA ;
Satkunarajah, M ;
McIntosh, CHS ;
Scrocchi, LA ;
Flamez, D ;
Schuit, F ;
Drucker, DJ ;
Wheeler, MB .
DIABETES, 1998, 47 (07) :1046-1052